All News
OP0053 #EULAR2024 @RheumNow #EULARBest
Effect of #RTX in preclinical #RheumatoidArthritis
RA-risk pts given 1 dose PBO or 1000mg RTX
RTX in RA-risk pts delayed onset of RA by 1yr; no benefit on QoL
Pts developing RA: RTX didn't alter PROs or disease severity when developing RA
Mrinalini Dey DrMiniDey ( View Tweet)
Genetic Risk scoring can predict adverse outcomes in #SLE #EULAR2024 @RheumNow https://t.co/g9kGdRkCOh
Bella Mehta bella_mehta ( View Tweet)
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT:
data now out to 60w
good humoral and cellular response in most, even without MTX withheld
(& good safety too)
Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020 @RheumNow https://t.co/FqVCCwUJOg
Links:
David Liew drdavidliew ( View Tweet)
A potentially notable association between TNFi in PsA and an increased risk of ischemic heart diseases and heart failure compared to IL-17i treatment. Limitations of the study noted. This may be due to patient selection and channeling of patients to the TNFi group and more… https://t.co/Q2LotHZwjQ https://t.co/uwl6vBIMsb
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Systematic Review of #SLE pregnancies in Latin America – 44articles, 4K patients, Hispanic/ Latino with increased preeclampsia when they have LN #EULAR2024 Abst#0986 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
AMPLIFIED study:
abatacept vs adalimumab in RF+ACPA+ early RA
Not a single blink of difference.
Maybe for high CCP titre but the inverse for low CCP.
Sadly, theoretical mechanistic benefit doesn’t always wash out. We’ll keep on looking for predictors #EULAR2024 OP0007 @RheumNow https://t.co/IswCub9lLn
David Liew drdavidliew ( View Tweet)
Digital technologies and health in #SLE can be integrated at several stages, but still a needs a bridge between #AI and #humanintellegence #EULAR2024 @Lupusreference @RheumNow https://t.co/1aN8QPgVWn
Links:
Bella Mehta bella_mehta ( View Tweet)
Treat to target in #lupus - difficult for many reasons.
Also may be too much of a restrictive strategy.
@Lupusreference talks about DORIS definition of remission- however mentions may be difficult to do in daily practice #EULAR2024 @rheumnow https://t.co/XqiubfOz2n
Links:
Bella Mehta bella_mehta ( View Tweet)
Many drugs in the horizon for #lupus @Lupusreference lecture #EULAR2024
Loved the timeline of all major drug -phase 2 and 3 drugs.
Need for new strategies in Lupus – outcomes and survival is plateauing!
@RheumNow https://t.co/Ue239woQJr
Links:
Bella Mehta bella_mehta ( View Tweet)
Clinical pearl in #SLE pregnancies #EULAR2024 Whats new in lupus session.
Measure Hydroxychloroquine levels! @RheumNow https://t.co/OnktkMSPR5
Bella Mehta bella_mehta ( View Tweet)
Lupus GPT - a chatbot which is much more relevant to Lupus - for patients and physician question etc. #EULAR2024 - Will be functional soon.
Looking forward to playing with this. #LLMs #ChatGPT
More to come. @RheumNow https://t.co/mGXG6A85Hx
Bella Mehta bella_mehta ( View Tweet)
Biomarkers in Lupus - Urine biomarkers @andreafava in #EULAR2024
We need these biomarkers to come in mainstream clinical practice if they work better than proteinuria. @RheumNow https://t.co/i7aeBx6qRR
Bella Mehta bella_mehta ( View Tweet)
@Lupusreference noted data suggests pulse IV methylprednisolone yields better outcomes for LN than adjustments of chronic oral steroids. #EULAR24 @RheumNow https://t.co/n93x036uIn
TheDaoIndex KDAO2011 ( View Tweet)
Precision medicine in Lupus is far from reality today. @Lupusreference @RheumNow #EULAR2024
Bella Mehta bella_mehta ( View Tweet)
Whats new in Lupus #EULAR2024 @Lupusreference lecture - many pearls.
Corticosteroids IV may be the way to go - referencing @AliDuarteMD team (better outcomes compared to oral steroids)
@RheumNow https://t.co/Fz1dZUVomF
Links:
Bella Mehta bella_mehta ( View Tweet)
Should we treat to target (T2T) for #SLE or just do SOC and gestalt (as most do in clinical practice)? @Lupusreference #EULAR24 @RheumNow
TheDaoIndex KDAO2011 ( View Tweet)
💊 Difficult-to-treat #SpA & #PsA
🤔 What are the challenges in assessing persistently active disease?
🗣️ Vinod Chandran takes us through the pearls and pitfalls in assessing D2T disease
🌎 Great to see #comorbidities highlighted
@RheumNow
#EULAR2024 https://t.co/x4jUTOC3li
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
Dr. G Schett reported using CAR-T cell Rx in patients w/ 1. pedi-SLE 2. CNS lupus 3. refractory cases with success. Post- Rx vaccine response is fine, infection risk is less since pts no longer need steroids. He is still following the pts for relapse and AEs @RheumNow #EULAR24
TheDaoIndex KDAO2011 ( View Tweet)
Consider the source and type of pain when managing axSpA including nociplastic pain. Difficult to treat axSpA #EULAR2024 Rudwaleit M @RheumNow https://t.co/4rszIyw5V6
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
CAR-T effective B cell depletion preserving plasma cell function @rheumnow #EULAR2024 https://t.co/mYmwC2cV6e
Peter Nash drpnash ( View Tweet)